Chesta J, Antezana C
Centro de Gastroenterología, Hospital José Joaquín Aguirre, Universidad de Chile, Santiago.
Rev Med Chil. 1994 Apr;122(4):365-71.
Despite non absorbable antibiotics and neomycin may have antagonistic effects on intestinal bacterial environment, both have synergistic effects in the treatment of hepatic encephalopathy. This could be due to their action on different enteric flora or a neomycin induced carbohydrate malabsorption.
To investigate the effects of neomycin on intestinal digestion, absorption and fermentation of carbohydrates in patients with liver cirrhosis.
Thirty eight Child B or C cirrhotic patients separated in three groups; subjects within each group were randomized to receive neomycin (2/g/day for 10 days, n = 8) or placebo (n = 4). Absorption of lactose and d-xylose and fermentation of d-xylose, lactose and lactulose (measured using hydrogen breath tests) were studied before and after the treatment period.
Neomycin did not change lactose fermentation but reduced plasma glucose rise after lactose ingestion (38.8 +/- mg/dl to 22 +/- 6 mg/dl p < 0.05). Plasma d-xylose levels at 30 min and its 5 h urinary excretion were reduced by neomycin from 19 +/- 3 to 9 +/- 2 mg/dl and from 4.9 +/- 0, 8 to 2.6 +/- 0.3 g/5h respectively (p < 0.05). Fermentation of d-xylose, lactose and lactulose was not reduced by neomycin. No significant changes were observed after placebo treatment.
Neomycin therapy is associated with a reduction of intestinal digestion and absorption of carbohydrates, preserving bacterial fermentation capacity, probably increasing the non absorbable carbohydrate load reaching the colon.
尽管不可吸收抗生素和新霉素可能对肠道细菌环境有拮抗作用,但二者在肝性脑病治疗中具有协同作用。这可能归因于它们对不同肠道菌群的作用,或者新霉素诱导的碳水化合物吸收不良。
研究新霉素对肝硬化患者肠道碳水化合物消化、吸收及发酵的影响。
38例Child B或C级肝硬化患者分为三组;每组患者随机接受新霉素(2g/天,共10天,n = 8)或安慰剂(n = 4)治疗。在治疗前后研究乳糖和d-木糖的吸收以及d-木糖、乳糖和乳果糖的发酵情况(采用氢呼气试验测量)。
新霉素未改变乳糖发酵,但降低了乳糖摄入后血浆葡萄糖的升高幅度(从38.8±mg/dl降至22±6mg/dl,p < 0.05)。新霉素使30分钟时血浆d-木糖水平及其5小时尿排泄量分别从19±3mg/dl降至9±2mg/dl,从4.9±0.8g/5h降至2.6±0.3g/5h(p < 0.05)。新霉素未降低d-木糖、乳糖和乳果糖的发酵。安慰剂治疗后未观察到显著变化。
新霉素治疗与肠道碳水化合物消化和吸收减少相关,同时保留细菌发酵能力,可能增加到达结肠的不可吸收碳水化合物负荷。